HKU Scholars Hub: Browsing DSpace

Browsing by Author Dela Cruz, C

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 中

or enter first few letters:

Showing results 1 to 4 of 4

	Title	Author(s)	Issue Date	Views
	Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial Journal:Lancet	El-Khoueiry, AB Sangro, B Yau, TCC Crocenzi, TS Kudo, M Hsu, C Kim, TY Choo, SP Trojan, J Welling, TH Meyer, T Kang, YK Yeo, W Chopra, A Anderson, J Dela Cruz, C Lang, L Neely, J Tang, H Dastani, HB Melero, I	2017	151
	Phase 1/2 Safety and Antitumor Activity of Nivolumab in Patients With Advanced Hepatocellular Carcinoma: Interim Analysis of the CheckMate 040 Dose-Escalation Study Proceeding/Conference:Liver Cancer	El-Khoueiry, AB Sangro, B Yau, TCC Crocenzi, TS Welling, TH, III Yeo, W Chopra, A Anderson, J dela Cruz, C Lang, L Neely, J Melero, I	2016	64
	A randomized, double-blind, multicenter phase 3 study of brivanib versus placebo as adjuvant therapy to trans-arterial chemoembolization in patients with unresectable hepatocellular carcinoma: initial results Proceeding/Conference:Annual Conference of the International Liver Cancer Association, ILCA 2013	Kudo, M Finn, R Poon, RTP Blanc, JF Han, G Yan, L Yang, J Lu, L Tak, WY XU, X Lee, JH Lin, SM Wu, C Tanwandee, T Shao, G Walters, L Dela Cruz, C Poulart, V Wang, JH	2013	42
	Safety and Antitumor Activity of Nivolumab (Nivo) in Patients (pts) with Advanced Hepatocellular Carcinoma (HCC): Interim Analysis of Dose-Expansion Cohorts from the Phase 1/2 CheckMate-040 Study Proceeding/Conference:Liver Cancer	Sangro, B Melero, I Yau, TCC Hsu, C Kudo, M Crocenzi, TS Kim, TY Choo, SP Trojan, J Meyer, T Kang, YK Anderson, J dela Cruz, C Lang, L Neely, J El-Khoueiry, AB	2016	151

Showing results 1 to 4 of 4